Trial site
Florida Research Institute
Lakewood Rch, Florida 34211, United StatesNot linked to an institution yet
- 16running trials
- 10closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 212 trials
- Phase 310 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Completed8 trials
- Recruiting7 trials
- Terminated2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company4 trials
- Madrigal Pharmaceuticals, Inc.4 trials
- Boehringer Ingelheim3 trials
- Gilead Sciences3 trials
- Inventiva Pharma2 trials
- and 10 more
Running trials
Not yet recruiting
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
NCT07848191· Phase 4· Madrigal Pharmaceuticals, Inc.· Source
Contact: Tom Hare
Recruiting
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
NCT07841977· Phase 2· Gilead Sciences· Source
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Contact: Manuel Rodriguez (principal investigator)
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101· Phase 2· Eli Lilly and Company· Source
Contact: Manuel Rodriguez (principal investigator)
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Manuel Rodriguez (principal investigator)
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308· Phase 2· Mirum Pharmaceuticals, Inc.· Source
Active, not recruiting
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
NCT04136002· Guardant Health, Inc.· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
NCT06247735· Phase 2· Kowa Research Institute, Inc.· Source
Completed
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
NCT06060665· Phase 3· Gilead Sciences· Source
Completed
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
NCT05232071· Phase 2· Inventiva Pharma· Source
Completed
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source
Completed
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· Phase 2· Gilead Sciences· Source
Terminated
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
NCT04267393· Phase 2· Bristol-Myers Squibb· Source
Completed
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
NCT04480840· Phase 2· Pliant Therapeutics, Inc.· Source
Terminated
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
NCT04365868· Phase 2/3· Galectin Therapeutics Inc.· Source
Completed
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
NCT04321031· Phase 2· Pfizer· Source
Completed
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
NCT02914535· Phase 3· Alfasigma S.p.A.· Source
Report an error